Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A

Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A

SSSE:600252
2.07
CNY
-0.05
(-2.36%)
-0.18EPS
7.01BMarket Cap
Guangxi Wuzhou Zhongheng Group Co., Ltd. Class A
SSE:600252
(Shanghai Stock Exchange)

Recent

price

2.07

P/E

ratio

- -

div

yld

0.71%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.47
0.35
0.59
1.22
0.93
0.39
0.48
0.58
0.97
1.13
1.05
0.92
0.79
0.87
0.62
0.56
0.41
Revenue per Share
0.12
0.11
0.21
0.23
0.46
0.15
0.14
0.17
0.18
0.22
0.16
0.09
0.02
0.02
-0.11
-0.11
-0.13
Basic EPS, GAAP
-0.04
-0.21
0.22
0.15
0.05
-0.01
0.4
0.2
0.19
0.15
0.14
-0.11
-0.11
0.07
0.08
-0.04
- -
Free Cash Flow per Basic Share
0.02
0.04
0.06
0.08
0.08
0.32
- -
0.04
0.06
0.06
0.11
0.1
0.05
0.03
0.03
0.02
0.01
Dividend per Share
0.4
0.61
0.95
1.13
1.7
1.42
1.53
1.61
1.7
1.84
1.97
1.91
1.88
1.9
1.8
1.69
1.63
Book Value per Share
0.35
0.56
0.89
0.98
1.57
1.3
1.41
1.49
1.6
1.74
1.71
1.63
1.62
1.7
1.63
1.55
1.49
Tangible Book Value per Share
3,007
3,279
3,278
3,276
3,466
3,468
3,495
3,558
3,408
3,386
3,518
3,425
3,421
3,427
3,369
3,121
3,166
Basic Weighted Avg Shares
1,426
1,151
1,946
3,997
3,214
1,343
1,670
2,048
3,299
3,814
3,676
3,162
2,714
2,969
2,105
1,749
1,304
Sales/Revenue/Turnover
38.53
36.6
29.56
19.96
32.68
18.53
39.25
34.16
19.38
16.83
12.42
5.62
2.53
1.85
-5.64
-10.16
-13.67
Operating Margin (%)
26
37
45
52
67
84
82
86
92
98
176
191
190
195
167
157
- -
Depreciation Expense
371
375
684
743
1,595
520
489
605
613
745
563
307
79
84
-377
-357
-419
Net Income, GAAP
15.96
17.63
17.44
15.65
19.52
19.91
19.49
18.74
12.99
17.55
26.52
25.19
80.58
63.17
- -
- -
- -
Effective Tax Rate (%)
26.01
32.59
35.15
18.58
49.61
38.73
29.3
29.54
18.59
19.53
15.31
9.71
2.91
2.84
-17.91
-20.42
-32.09
Profit Margin (%)
1,210
1,112
1,275
1,055
2,891
2,116
2,213
2,469
2,757
2,304
2,336
4,250
4,219
4,240
3,638
2,985
2,638
Working Capital
705
542
206
- -
- -
- -
- -
- -
- -
- -
191
204
650
553
473
476
168
LT Debt
1,308
2,000
3,105
3,689
5,918
4,955
5,325
5,597
5,913
6,397
8,228
8,690
8,289
8,277
7,515
6,744
6,528
Total Equity
23.96
10.57
19.63
14.64
25.16
7.96
9.16
11.28
10.52
11.93
3.07
1.31
0.08
0.48
- -
- -
- -
Return on Invested Capital (%)
22.22
14.05
19.53
18.65
28.32
9.05
9.19
11.08
9.76
11.99
11.48
4.81
1.58
1.6
- -
- -
- -
Return on Capital (%)
39.63
22.72
26.84
21.89
33.22
9.58
9.53
11.08
10.66
12.11
8.5
4.56
1.2
1.29
-5.99
-6.27
-7.62
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,641
1,451
577
LT Borrowings
458
387
161
LT Finance Leases
8
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,184
3,184
3,184
Market Capitalization
8,120
5,604
7,005

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,597
5,387
4,103
Cash, Cash Equivalents & STI
3,794
3,581
2,412
Accounts Receivable, Net
372
400
354
Inventories
641
651
637
Total Current Liabilities
2,632
2,467
1,465
Payables & Accruals
- -
- -
- -
ST Debt
1,641
1,451
577
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.64%
-3.72%
-10.26%
Free Cash Flow
-369.33%
-91.97%
-143.02%
Net Income, GAAP
-64.94%
-133.09%
-5.28%
Sales/Revenue/Turnover
5.53%
-12.96%
-16.92%
Total Cash Common Dividend
- -
-29.69%
-39.17%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
760
605
516
178
2,105
2025
522
509
414
303
1,749
2026
355
370
276
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.01
- -
-0.12
-0.11
2025
0.01
- -
- -
-0.12
-0.11
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
- -
- -
0.03
2025
- -
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -
Business
Guangxi Wuzhou Zhongheng Group Co., Ltd. manufactures and distributes pharmaceuticals, traditional Chinese medicines, health products, and daily consumer goods; its core business encompasses pharmaceutical manufacturing, health consumption, research and development of traditional Chinese medicine resources, cosmetics, and pharmaceutical distribution. The company produces injectable thrombotron (freeze-dried), Chinese dumpling pills, gout tablets, shedan chuanbei liquid, Kun Yue'an, clam oral liquid, xueshuantong for shooting, zhonghua dieda pills, angong niuhuang pills, fuyanjie capsules, jieshitong tablets, yanjianning tablets, and sodium fluorescein injection under brands including Zhonghua, Chenzhong, and Zhongheng, covering cardiovascular, cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system, antineoplastic drugs, digestive drugs, parenteral nutritional drugs, anti-infectives, and large infusions; it also offers chemical preparations and raw materials, traditional health products such as turtle jelly paste and derivatives, turtle jelly, turtle jelly powder, Liubao tea and drinks, instant porridge, beverages, solid drinks, innovative traditional Chinese medicines, high-end generic pharmaceuticals, health foods, daily necessities, and consumer care items including 37 targeted toothpaste, smart electric toothbrushes, bio-enzyme mouthwashes, detergents, laundry detergent, soap, and shampoo under Field Seven, Tianqi Baby, Jianguo, Easy Butler, and Pure Cotton Era brands. Founded in 1993 and listed on the Shanghai Stock Exchange in 2000 under ticker 600252.SS, the company is headquartered at No. 1 Industrial Avenue, Wuzhou Industrial Park, Wuzhou, Guangxi Zhuang Autonomous Region, China, with primary operations in China; its subsidiary Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. serves as a leading chain enterprise in Guangxi, and the firm ranks among China's top 100 pharmaceutical industrial and traditional Chinese medicine enterprises while being controlled by Guangxi Investment Group Co., Ltd. Recent developments include Guangxi Investment Group Financial Holdings Company Limited's completion of a CNY 4.1 billion acquisition of a 26.89% stake from Guangxi Investment Group Co., Ltd. on October 31, 2025, following securities transfer registration confirmation; the company also announced a CNY 500 million equity buyback in January 2025, a subsidiary's selection for traditional Chinese medicine procurement in February 2025, and supplementary approval for an antibiotic product. Additional activities span health food production, pharmaceutical distribution, project investment and management, real estate development and operation, and cosmetics.